A Phase 1/2 interventional study of FT-001 Low Dose and FT-001 Mid Dose in Biallelic RPE65 Mutation-associated Retinal Dystrophy, sponsored by Frontera Therapeutics. Recruiting at 1 site in China. Open to participants aged 8 Years to 45 Years. Per ClinicalTrials.gov, last updated 2023-05-15.
Sponsored by Frontera Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Retinal Dystrophies with a site in China — 6 open to participants now, 9 under way, 1 of them phase 3. Retinal Dystrophies · China.
Among the 10 studies in Retinal Dystrophies with a site in China, this one is one of 2 that started in 2022, is one of 2 in phase 1/2, and was the 3rd registered.
60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.
Browse Retinal Dystrophies studies →6 of the 10 studies in Retinal Dystrophies with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18–55
Zhongmou Therapeutics · Sites in China
Healthy volunteers
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 4+
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) · Sites in China, United States, Australia
Ages 18–65
Institute of Molecular and Clinical Ophthalmology Basel · Sites in China, United States, Germany and 4 more countries
Healthy volunteers
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.
This study: 8 Years to 45 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 2 · Phase 3 1
First in 2018; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 9 is below the median of 18 across 34 interventional studies indexed under Retinal Dystrophies.
Median enrollment 9 across the 7 interventional studies, 500 across the 3 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 7 most frequent:
Frontera Therapeutics is the lead sponsor of 7 studies on the registry; 7 are open to participants now.
Frontera Therapeutics has 1 study filed under Retinal Dystrophies — fewer than ten, so there is no comparison to draw.
4 of the studies in Retinal Dystrophies with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05294978Institute of Molecular and Clinical Ophthalmology BaselEyeConic: Qualification for Cone-Optogenetics | 2026-12 |
| NCT07063030Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineA Study of LX107 Gene Therapy in AIPL1-IRD Patients | 2026-12-31 |
| NCT07085533Zhongmou TherapeuticsNatural History Study of Inherited Retinal Diseases | 2027-06-04 |
| NCT07656753Peking Union Medical College HospitalSafety and Efficacy Study of PUMCH-E111 Injection in Subjects With RLBP1 Related Inherited Retinal Dystrophy | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Retinal Dystrophies with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of subretinal administration of FT-001 in subjects with biallelic RPE65 mutation-associated retinal dystrophy.
This study is a multi-center, open-label, phase I/II clinical study to evaluate the safety, tolerability, efficacy, immunogenicity, and in vivo biodistribution characteristics of FT-001 in subjects with biallelic RPE65 mutation-associated retinal dystrophy. Assessments will include visual acuity, vector shedding, immunogenicity and adverse events. Participants will be monitored for 5 years after treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intraocular administration of a single low dose of range FT-001
Genetic: FT-001 Low Dose
Intraocular administration of a single Mid dose of range FT-001
Genetic: FT-001 Mid Dose
Intraocular administration of a single High dose of range FT-001
Genetic: FT-001 High Dose
Comparison of different dosages of FT-001
Comparison of different dosages of FT-001
Comparison of different dosages of FT-001
Safety of FT-001(incidence of ocular and non-ocular AEs and SAEs)
Incidence of ocular and non-ocular AEs and SAEs
Time frame: 52 weeks
Changes in visual function from baseline
Changes in visual function from baseline as assessed by FST
Time frame: 52 weeks
Changes in visual function from baseline
Changes in visual function from baseline as assessed by Mobility courses
Time frame: 52 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for Nov 2025, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Frontera Therapeutics